Chylomicron remnants are increased in the postprandial state in CD36 deficiency

Journal of Lipid Research

Volumn 50, Issue 5, 2009, Pages 999-1111

  Masuda, Daisaku ^a   Hirano, Ken Ichi ^a   Oku, Hiroyuki ^a   Sandoval, Jose C ^a   Kawase, Ryota ^b   Yuasa Kawase, Miyako ^a   Yamashita, Yasushi ^c   Takada, Masanori ^b   Tsubakio Yamamoto, Kazumi ^a   Tochino, Yoshihiro ^a   Koseki, Masahiro ^a   Matsuuura, Fumihiko ^a   Nishida, Makoto ^d   Kawamoto, Toshiharu ^c   Ishigami, Masato ^a   Hori, Masatsugu ^a   Shimomura, Iichiro ^a   Yamashita, Shizuya ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kawasaki Hospital   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Apolipoprotein B 48; Atherosclerosis; Free fatty acids; Free glycerol; Small dense LDL; TG rich lipoproteins

Indexed keywords

APOLIPOPROTEIN B48; CD36 ANTIGEN; CHYLOMICRON REMNANT; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; FATTY ACID SYNTHASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; CHYLOMICRON; LIPOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FAT TOLERANCE TEST; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; FEMALE; GENE EXPRESSION; GLYCEROL BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INTESTINE LYMPH; LIPID ABSORPTION; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTPRANDIAL STATE; PRIORITY JOURNAL; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DIET RESTRICTION; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; INTESTINE MUCOSA; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; MOUSE MUTANT; PARTICLE SIZE; PHYSIOLOGY;

AGED; ANIMALS; ANTIGENS, CD36; CHYLOMICRONS; DIETARY FATS; FASTING; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTESTINAL MUCOSA; LIPID METABOLISM; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PARTICLE SIZE; POSTPRANDIAL PERIOD;

EID: 67649381418     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P700032-JLR200     Document Type: Article

References (37)

1. Wilson, P. W. F., R. B. D'Agostino, D. Levy, A. M. Belanger, H. Silbershatz, and W. B. Kannel. 1998. Prediction of coronary heart disease using risk factor categories. Circulation. 97: 1837-1847.
2. Hokanson, J. E., and M. A. Austin. 1996. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population based prospective studies. J. Cardiovasc. Risk. 3: 213-219.
3. Zilversmit, D. B. 1979. Atherogenesis: a postprandial phenomenon. Circulation. 60: 473-485.
4. Havel, R. J. 1994. Postprandial hyperlipidemia and remnant lipoproteins. Curr. Opin. Lipidol. 5: 102-119.
5. Cohn, J. S., C. Marcoux, and J. Davignon. 1995. Detection, quantification, and characterization of potentially atherogenic triglyceriderich remnant lipoproteins. Arterioscler. Thromb. Vasc. Biol. 19: 2474-2486.
6. Funada, J., M. Sekiya, T. Otani, K. Watanabe, M. Sato, and H. Akutsu. 2004. The close relationship between postprandial remnant metabolism and insulin resistance. Atherosclerosis. 172: 151-154.
7. Yamashita, S., K. Hirano, T. Kuwasako, M. Janabi, Y. Toyama, M. Ishigami, and N. Sakai. 2007. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem. 299: 19-22.
8. Poirier, H., P. Degrace, I. Niot, A. Bernard, and P. Besnard. 1996. Localization and regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. Eur. J. Biochem. 238: 368-373.
9. Miyaoka, K., T. Kuwasako, K. Hirano, S. Nozaki, S. Yamashita, and Y. Matsuzawa. 2001. CD36 deficiency is associated with insulin resistance. Lancet. 357: 686-687.
10. Kuwasako, T., K. Hirano, N. Sakai, M. Ishigami, H. Hiraoka, M. J. Yakub, K. Yamauchi-Takihara, S. Yamashita, and Y. Matsuzawa. 2003. Lipoprotein abnormalities in human genetic CD36 deficiency associated with insulin resistance and abnormal fatty acid metabolism. Diabetes Care. 26: 1647-1648.
11. Hajri, T., X. X. Han, A. Bonen, and N. A. Abumrad. 2002. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J. Clin. Invest. 109: 1381-1389.
12. Febbraio, M., N. A. Abumrad, D. P. Hajjar, K. Sharma, W. Cheng, S. F. Pearce, and R. L. Silverstein. 1999. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274: 19055-19062.
13. Drover, V. A., M. Ajmal, F. Nassir, N. O. Davidson, A. M. Nauli, D. Sahoo, P. Tso, and N. A. Abumrad. 2005. CD36 deficiency impairs intestinal lipid secretion and clearance of chylomicrons from the blood. J. Clin. Invest. 115: 1290-1297.
14. Goudriaan, J. R., M. A. den Boer, P. C. Rensen, M. Febbraio, F. Kuipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol. 2005. CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J. Lipid Res. 46: 2175-2181.
15. The Committee for Japanese Definition of Metabolic Syndrome. 2005. Metabolic syndrome - definition and diagnostic criteria in Japan [in Japanese]. J Jpn Soc Int Med. 94: 794-203.
16. Sakai, N., Y. Uchida, K. Ohashi, T. Hibuse, Y. Saika, Y. Tomari, S. Kihara, H. Hiraoka, T. Nakamura, S. Ito, et al. 2003. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J. Lipid Res. 44: 1256-1262.
17. Miyauchi, K., N. Kayahara, M. Ishigami, H. Kuwata, H. Mori, H. Sugiuchi, T. Irie, A. Tanaka, S. Yamashita, and T. Yamamura. 2007. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin. Chem. 53: 2128-2135.
18. Usui, S., Y. Hara, S. Hosaki, and M. Okazaki. 2002. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J. Lipid Res. 43: 805-814.
19. Okazaki, M., S. Usui, A. Fukui, I. Kubota, and H. Tomoike. 2006. Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin. Chem. 52: 2049-2053.
20. Moore, K. J., J. El Khoury J, L. A. Medeiros, K. Terada, C. Geula, A. D. Luster, and M. W. Freeman. 2002. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 277: 47373-47379.
21. Lutz, E. P., M. Merkel, Y. Kako, K. Melford, H. Radner, J. L. Breslow, A. Bensadoun, and I. J. Goldberg. 2001. Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues. J. Clin. Invest. 107: 1183-1192.
22. Bollman, J. L., J. C. Cain, and J. H. Grindlay. 1949. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J. Lab. Clin. Med. 33: 1349-1352.
23. Nishida, Y., K. Hirano, K. Tsukamoto, M. Nagano, C. Ikegami, K. Roomp, M. Ishihara, N. Sakane, Z. Zhang, K. Tsujii, et al. 2002. Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency. Biochem. Biophys. Res. Commun. 290: 713-721.
24. Karpe, F. 1999. Postprandial lipoprotein metabolism and atherosclerosis. J. Intern. Med. 246: 341-355.
25. Krauss, R. M. 1991. Low density lipoprotein subclass and risk of coronary disease. Curr. Opin. Lipidol. 4: 248-252.
26. Syvänne, M., and M. R. Taskinen. 1997. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 350: 20-23.
27. Lemieux, I., C. Couillard, A. Pascot, N. Bergeron, D. Prud'homme, J. Bergeron, A. Tremblay, C. Bouchard, P. Mauriege, and J. P. Després. 2000. The small dense LDL phenotype as a correlate of postprandial lipemia in men. Atherosclerosis. 153: 423-432.
28. Haidari, M., N. Leung, F. Mahbub, K. D. Uffelman, R. Kohen-Avramoglu, G. F. Lewis, and K. Adeli. 2002. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. J. Biol. Chem. 277: 31646-31655.
29. Ockner, R. K., F. B. Hughes, and K. J. Isselbacher. 1969. Very low density lipoproteins in intestinal lymph: origin, composition, and role in lipid transport in the fasting state. J. Clin. Invest. 48: 2079-2088.
30. Shiau, Y. F., D. A. Popper, M. Reed, C. Umstetter, D. Capuzzi, and G. M. Levine. 1985. Intestinal triglycerides are derived from both endogenous and exogenous sources. Am. J. Physiol. Gastrointest. Liver Physiol. 248: 164-169.
31. Luchoomun, J., and M. M. Hussain. 1999. Assembly and secretion of chylomicrons by differentiated caco-2 cells. J. Biol. Chem. 274: 19565-19572.
32. Pravenec, M., V. Landa, V. Zidek, A. Musilova, V. Kren, L. Kazdova, T. J. Aitman, A. M. Glazier, A. Ibrahimi, N. A. Abumrad, et al. 2001. Transgenic rescue of defective CD36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat. Genet. 27: 156-158.
33. Ma, X., S. Bacci, W. Mlynarski, L. Gottardo, T. Soccio, C. Menzaghi, E. Iori, R. A. Lager, A. R. Shroff, E. V. Gervino, et al. 2004. A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians. Hum. Mol. Genet. 13: 2197-2205.
34. Kajihara, S., A. Hisatomi, Y. Ogawa, T. Yasutake, T. Yoshimura, T. Hara, T. Mizuta, I. Ozaki, N. Iwamoto, and K. Yamamoto. 2001. Association of the Pro90Ser CD36 mutation with elevated free fatty acid concentrations but not with insulin resistance syndrome in Japanese. Clin. Chim. Acta. 314: 125-130.
35. Carlsson, M., Y. Wessman, P. Almgren, and L. Groop. 2000. High levels of nonesterified fatty acids are associated with increased familial risk of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 20: 1588-1594.
36. Pirro, M., P. Mauriege, A. Tchernof, B. Cantin, G. R. Dagenais, J. P. Despres, and B. Lamarche. 2002. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis. 160: 377-384.
37. Febbraio, M., E. A. Podrez, J. D. Smith, D. P. Hajjar, S. L. Hazen, H. F. Hoff, K. Sharma, and R. L. Silverstein. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105: 1049-1056.